Serum sickness

SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes

Retrieved on: 
Monday, October 2, 2023
SAB, JDRF, Maintenance, Serum sickness, Insulin, Human, Diabetes, Investment, T1D, Cell, Immunotherapy, Patient, Risk, Offering, Immunoglobulin G, ATG, Blaine Higgs, Conditional sentence, Pharmaceutical industry, Bank, Vaccine

SIOUX FALLS, S.D., Oct. 02, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced the Company has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell shares of preferred stock in a private placement (the “Offering”). The Offering will provide up to $130 million in gross proceeds to SAB, which will be used to fund the company’s lead research program, SAB-142, a potential disease-modifying treatment for T1D. The full proceeds, when funded, are expected to fund the company through 2026 and topline Phase II results.

Key Points: 
  • The Offering will provide up to $130 million in gross proceeds to SAB, which will be used to fund the company’s lead research program, SAB-142, a potential disease-modifying treatment for T1D.
  • The full proceeds, when funded, are expected to fund the company through 2026 and topline Phase II results.
  • The transaction is being led by RA Capital Management, with participation from BVF Partners, Sessa Capital, Commodore Capital, RTW Investments, Marshall Wace, and the JDRF T1D Fund.
  • SAB will use the funds to clinically advance SAB-142, its lead therapeutic candidate for T1D, which is expected to advance to clinical trials in Q4 2023.

SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results

Retrieved on: 
Monday, August 21, 2023
SAB, Post-exposure prophylaxis, GLP, JDRF, Serum sickness, New Animal Drug Application, LLP, BIO, Omicron, Higgs, KOL, University, FDA Center for Devices and Radiological Health, Partnership, Diabetes, Blas, T1D, Type A and Type B personality theory, Safety, Pediatric endocrinology, COVID-19, Center for Biologics Evaluation and Research, BTD, G&A, Immunotherapy, Antibody, Breakthrough therapy, Professor, Federation, HIV disease progression rates, Patient, NADA, Administration, International Society, ATG, Endocrinology, Entrepreneurship, Research and development, Blaine Higgs, Federation of Clinical Immunology Societies, FDA, Private law, R, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, US Foods, NIH, Treatment, Type 1 diabetes, Food, Vaccine, Pharmaceutical industry, Medical device, Cryptocurrency, Research

SIOUX FALLS, S.D., Aug. 21, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulins (hIgG), also known as fully-human polyclonal antibodies, without the need for human donors, today reported financial results for the second quarter ended June 30, 2023, and provided a company update.

Key Points: 
  • SIOUX FALLS, S.D., Aug. 21, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulins (hIgG), also known as fully-human polyclonal antibodies, without the need for human donors, today reported financial results for the second quarter ended June 30, 2023, and provided a company update.
  • "We are pleased to share the significant progress achieved during the second quarter of 2023.
  • On August 21, 2023, we announced that EisnerAmper LLP was appointed as our independent registered public accounting firm for the fiscal year ending December 31, 2023, effective August 22, 2023.
  • The decrease was primarily due to discretionary cost reduction measures and increased efficiencies as we continue to mature as a publicly traded company.

SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023

Retrieved on: 
Wednesday, June 21, 2023
SAB, GLP, Serum sickness, Insulin, NOAEL, CTA, Research, Disease, Immunotherapy, Type, Federation, Investigational New Drug, MD, Patient, Annual general meeting, ATG, Kidney transplantation, Rabbit, Douglas Higgs, Federation of Clinical Immunology Societies, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Type 1 diabetes, Food, Safety, Vaccine, Pharmaceutical industry, Online shopping, T1D, IND

SIOUX FALLS, S.D., June 21, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human multi-target immunoglobulin (hIgG) antibodies (fully-human polyclonal antibodies) without the need for human donors, today announced the presentation of positive safety and pharmacologic data from a GLP toxicology study for SAB-142, a first in class fully human immunotherapeutic being developed for delaying onset and progression of Type 1 Diabetes (T1D), at the Federation of Clinical Immunology Societies (FOCIS) in Boston. Results from the IND-enabling GLP tox study confirmed that SAB-142 affects the same subsets of immune cells associated with T1D as commercially available rabbit-derived anti-thymocyte globulin (rATG) in vivo.

Key Points: 
  • SAB-142's unique multi-target strategy can be directed at the multiple immunological cell subsets associated with T1D and other autoimmune diseases.
  • SAB will present a poster titled, “Safety and Pharmacodynamic Effects of Novel Fully Human Anti-Thymocyte Polyclonal IgG Antibodies in an IND Enabling GLP Toxicology Study.
  • In the in vivo study conducted under GLP conditions, SAB-142 was administered at three dose levels of 1, 5, and 10 mg/kg.
  • More information on SAB’s T1D candidate, SAB-142, can be found on the pipeline page of SAB’s website: SAB-142: Type 1 Diabetes .

SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes

Retrieved on: 
Tuesday, January 10, 2023
IND, Immunotherapy, Degenerative disease, SAB, Toxicity, Therapy, T1D, Patient, FDA, MD, Serum sickness, Pharmaceutical industry, Vaccine

SAB will submit the IND filing within approximately 12 months.

Key Points: 
  • SAB will submit the IND filing within approximately 12 months.
  • SAB-142 is the first fully-human anti-thymocyte hpAB therapeutic currently being developed for delaying the progression and onset of type 1 diabetes, among other autoimmune indications.
  • As a fully-human polyclonal antibody therapeutic, SAB-142 may be administered multiple times without causing these immune-related adverse reactions, a desired factor when treating life-long diseases such as type 1 diabetes.
  • The study results showed that both SAB-142 and its active control, FDA-approved animal-derived polyclonal anti-thymocyte immunoglobulin, induced transient lymphodepletion confirming the SAB-142 mechanism of action.

SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes

Retrieved on: 
Monday, November 21, 2022
Autoimmune disease, Degenerative disease, SAB, Type 1, IND, Anaphylaxis, Patient, Mortality, Government, Toxicity, Genetic engineering, Pandemic, Clostridioides difficile infection, GLP, File, MD, Diabetes, Patent, Annual report, Infection, Serum sickness, Health, Therapy, Type, United States Department of Defense, Immunotherapy, Form 10-K, FDA, Probability, Vaccine, Pharmaceutical industry, T1D

In an IND-enabling GLP study, SAB-142 will be compared to an FDA-approved T-cell depleting therapeutic, to assess toxicity and pharmacodynamic effects.

Key Points: 
  • In an IND-enabling GLP study, SAB-142 will be compared to an FDA-approved T-cell depleting therapeutic, to assess toxicity and pharmacodynamic effects.
  • Type 1 diabetes is an autoimmune disease that represents a staggering unmet patient need, said Alexandra Kropotova, MD, Chief Medical Officer of SAB Biotherapeutics.
  • Patients in the Americas are disproportionally affected by Type 1 diabetes.
  • The initiation of this study supports the progression of our SAB-142 immunotherapeutic towards IND filing.